Xilio Therapeutics, Inc. — Director's Dealing 2021

Oct 28, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Xilio Therapeutics, Inc. (XLO)
CIK: 0001840233
Period of Report: 2021-10-26

Reporting Person: FMR LLC (See Remark 1)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-26	Common Stock	C	789473	—	Acquired	815788	Indirect
2021-10-26	Common Stock	C	686499	—	Acquired	1502287	Indirect
2021-10-26	Common Stock	C	28703	—	Acquired	1530990	Indirect
2021-10-26	Common Stock	C	372215	—	Acquired	372215	Indirect
2021-10-26	Common Stock	C	4465	—	Acquired	4465	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-26	Series A Preferred Stock	$	C	7500000	Disposed		Common Stock (789473)	Indirect
2021-10-26	Series A-1 Preferred Stock	$	C	6521739	Disposed		Common Stock (686499)	Indirect
2021-10-26	Series B Preferred Stock	$	C	272687	Disposed		Common Stock (28703)	Indirect
2021-10-26	Series B Preferred Stock	$	C	3536046	Disposed		Common Stock (372215)	Indirect
2021-10-26	Series B Preferred Stock	$	C	42421	Disposed		Common Stock (4465)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	26315	Indirect

Footnotes

F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.